North America Medical Enzyme Technology Market

Market Introduction

Enzymes are proteins produced in living cells of plants, animals, and microorganisms. All living organisms require enzymes for growth and for the production and utilization of energy which is essential for life. In the living cell, enzymes act as catalysts to speed up the chemical reactions which control life processes. Enzymes have been significant industrial products for more than a hundred years. However, the range of potential applications is increasing rapidly. With the advent of recombinant DNA technology, it has become possible to make formerly rare enzymes in large quantities and hence to reduce cost. Also, in pharmaceutical manufacturing, the desire to make chirally pure compounds is leading to new opportunities. Technological advances have facilitated the use of enzymes over an increasingly broad range of process conditions.

Thus, the significant increase in research and development activities is expected to create a significant demand for medical enzyme technology in the coming years, which is further anticipated to drive the medical enzyme technology market.

In the North American region, the US was profoundly affected by the outbreak of the COVID-19 pandemic. The country has marked the highest number of positive patients and still facing the second wave of COVID-19. Across the various healthcare sectors, the effect of a pandemic can be felt, resulting in various changes in the health care industry. Scientists are working together to produce and exchange genomic sequence data information, which can be used in disease detection and control efforts. The US is increasing its ability to track coronavirus mutations and has demand for digestive enzymes. It has also been documented that SARS-CoV-2 infection can cause liver damage, and that abnormal liver function and liver enzymes are associated with the severity of COVID-19. Extreme COVID-19 patients have higher levels of aspartate aminotransferase, alanine aminotransferase, and total bilirubin (TBL) than non-severe COVID-19 patients. Elevated hepatic enzymes are also more common in COVID-19 patients treated in the ICU compared to those not treated in the ICU. During the treatment of the first COVID-19 confirmed case in the United States, there was an overall increase in hepatic enzymes, indicating that SARS-CoV-2 infection would directly affect the liver. All such aspects will add to the future demand for the North America region's Medical Enzyme Technology market.

North America Medical Enzyme Technology Strategic Insights

Strategic insights for the North America Medical Enzyme Technology provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Medical Enzyme Technology Report Scope

North America Medical Enzyme Technology Regional Insights

The geographic scope of the North America Medical Enzyme Technology refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Medical enzyme technology market in North America is expected to grow from US$ 1,783.1 million in 2021 to US$ 2,857.6 million by 2028; it is estimated to grow at a CAGR of 7.0% from 2021 to 2028. Biopharmaceuticals are among the growing business segments of the pharmaceutical and biotechnology industries. Since their introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases, and they are increasingly used in nearly all medicine branches. Despite the immense time and financial effort required, the market of biopharmaceuticals is rapidly growing. In 2017, India-based Biocon received the US Food and Drug Administration (FDA) approval for Ogivri, a biosimilar to Herceptin (trastuzumab). That is the first biosimilar approved in the US to treat breast and stomach cancer and the second biosimilar approved in the country for cancer treatment.

Key Market Segments

In terms of enzyme type, the hydrolases segment accounted for the largest share of the North America medical enzyme technology market in 2020. In terms of application, the disease treatment segment accounted for the largest share of the North America medical enzyme technology market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the medical enzyme technology market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck Kgaa, Thermo Fisher Scientific Inc., Novozymes, Takeda Pharmaceutical Company Limited, Agilent Technologies, Inc., Genzyme Corporation, Asahi Kasei Corporation, Promega Corporation, Cytiva, and Amano Enzyme Inc.

Reasons to buy report

• To understand the North America Medical enzyme technology market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for North America Medical enzyme technology market
• Efficiently plan M&A and partnership deals in North America Medical enzyme technology market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America Medical enzyme technology market
• Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.

NORTH AMERICA MEDICAL ENZYME TECHNOLOGY MARKET SEGMENTATION

By Enzyme Type

• Digestive Enzymes
  • L-asparaginase
  • Lactase
  • Others
• Thrombolytic Enzymes
  • Streptokinase
  • Urokinase
  • Others
• Hydrolases Enzymes
  • Hyaluronidase
  • Lysozymes
  • Others
• Endonucleases Enzymes
  • Benzonase
  • Others

By Application

• Disease Treatment
• Diagnostic Tools
• Biomedical Research
• Others

By Country

• North America
  • US
  • Canada
  • Mexico

Companies Mentioned

1. Merck Kgaa
2. Thermo Fisher Scientific Inc.
3. Novozymes
4. Takeda Pharmaceutical Company Limited
5. Agilent Technologies, Inc.
6. Genzyme Corporation
7. Asahi Kasei Corporation
8. Promega Corporation
9. Cytiva
10. Amano Enzyme Inc.